The Filing Desk

Bionano Genomics vs Precipio

Bionano Genomics BNGO · Precipio PRPO · Life Sciences Tools & Services

Bionano Genomics reported revenue of $28 million in fiscal 2025, 1.2 times Precipio's $24 million in fiscal 2025. Bionano Genomics' revenue fell 7.4% in its latest year, and Precipio's grew 29.8%. Bionano Genomics had an operating margin of -117.0%, against -5.0% at Precipio. Free cash flow was −$16 million at Bionano Genomics and $0 million at Precipio.

Side by side

Bionano GenomicsPrecipio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$28M$24M
Revenue growth−7.4%29.8%
Revenue growth a year, last 5 years27.4%31.5%
Gross margin46.2%44.5%
Operating margin−117.0%−5.0%
Net margin−92.6%−1.5%
Free cash flow−$16M$0M
Free cash flow margin−57.3%1.5%
Return on capital−89.9%−7.8%
Net debt to EBITDA—−37.4x
Dividends and buybacks$0M$0M
Change in diluted share count328.4%9.5%
Last close$0.89$18.49
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score5 of 97 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Bionano GenomicsPrecipio
Operating margin
Percent of revenue
Bionano GenomicsPrecipio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Bionano GenomicsPrecipio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Bionano Genomics and Precipio pages.